二价RSVpreF孕期接种预防日本婴儿RSV疾病的效力与安全性:关键随机3期MATISSE试验的亚组分析
该研究为全球3期随机双盲安慰剂对照MATISSE试验的日本参与者亚组分析,孕妇24-36周随机1:1接种RSVpreF或安慰剂。结果显示婴儿出生后180天内RSV-MA-LRTI效力87.6%,严重RSV-MA-LRTI效力75.1%,未发现安全性问题。
要点
- 日本孕妇接种RSVpreF后,婴儿出生后180天内RSV-MA-LRTI疫苗效力为87.6%。
- 严重RSV-MA-LRTI在180天内的疫苗效力为75.1%,置信区间宽。
- 接种后1个月内不良事件率在RSVpreF组与安慰剂组相似,未发现安全性问题。
核心结论
- 日本参与者的安全性和效力数据与MATISSE总体结果一致,支持孕期RSVpreF接种对婴儿严重MA-RSV-LRTI/MA-RSV-LRTI的效力,未发现安全性问题。
研究设计与样本
- 全球3期随机双盲安慰剂对照MATISSE试验的日本参与者亚组分析,孕妇24-36周随机1:1接种RSVpreF或安慰剂。
- 日本230名孕妇接种RSVpreF、232名接种安慰剂,其婴儿分别有218名和216名纳入分析。
主要发现
- 婴儿出生后90天内RSV-MA-LRTI疫苗效力100.0%(95%CI 30.9-100.0;RSVpreF组0例,安慰剂组7例)。
- 婴儿出生后180天内RSV-MA-LRTI疫苗效力87.6%(95%CI 7.2-99.7;RSVpreF组1例,安慰剂组8例)。
- 婴儿出生后90天内严重RSV-MA-LRTI疫苗效力100.0%(95%CI -140.9-100.0;RSVpreF组0例,安慰剂组3例)。
- 婴儿出生后180天内严重RSV-MA-LRTI疫苗效力75.1%(95%CI -151.5-99.5;RSVpreF组1例,安慰剂组4例)。
- 接种/出生后1个月内不良事件率:RSVpreF组孕妇16.1%、婴儿48.6%,安慰剂组孕妇19.8%、婴儿50.5%;早产率RSVpreF组3.2%、安慰剂组6.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maternal vaccination with respiratory syncytial virus prefusion F vaccine (RSVpreF) is effective at preventing RSV-associated lower respiratory tract illness (LRTI) in newborns/infants. METHODS: This subgroup analysis from the global, phase 3, randomized, double-blind, placebo-controlled MATISSE (Maternal Immunization Study for Safety and Efficacy) trial evaluated participants enrolled in Japan. Pregnant women 24-36 weeks' gestation were randomized 1:1 to receive RSVpreF or placebo. Maternal safety endpoints included local reactions/systemic events within 7 days, adverse events (AEs) through 1 month, and serious AEs (SAEs) through 6 months after vaccination. In infants born to maternal participants, safety endpoints included specific birth outcomes, AEs through 1 month after birth, and SAEs and newly diagnosed chronic medical conditions through 12 or 24 months after birth. Vaccine efficacy in infants was assessed against RSV-positive, medically attended LRTI (RSV-MA-LRTI) and severe RSV-MA-LRTI through 180 days after birth. RESULTS: In Japan, 230 maternal participants received RSVpreF and 232 received placebo; 218 and 216 infants born to these mothers, respectively, were analyzed. Observed vaccine efficacy (95 % CIs) against infant RSV-MA-LRTI within 90 and 180 days after birth was 100.0 % (30.9, 100.0; RSVpreF, 0 cases; placebo, 7 cases) and 87.6 % (7.2, 99.7; RSVpreF, 1 case; placebo, 8 cases), respectively. Vaccine efficacy (95 % CIs) against severe RSV-MA-LRTI within 90 and 180 days was 100.0 % (-140.9, 100.0; RSVpreF, 0 cases; placebo, 3 cases) and 75.1 % (-151.5, 99.5; RSVpreF, 1 case; placebo, 4 cases), respectively. No safety concerns were identified. AE rates ≤1 month after vaccination/birth were similar in the RSVpreF (maternal, 16.1 %; infant, 48.6 %) and placebo (19.8 %; 50.5 %) groups. Preterm birth rates were also similar (RSVpreF, 3.2 %; placebo, 6.0 %). CONCLUSIONS: Safety and efficacy data in Japanese participants were consistent with overall MATISSE results, supporting the efficacy of maternal RSVpreF vaccination against severe MA-RSV-LRTI/MA-RSV-LRTI in infants, with no safety concerns. NCT04424316.
引用
- Otsuki T, Akada S, Anami A, et al. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. Vaccine. 2024. PMID: 38853036. doi:10.1016/j.vaccine.2024.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。